An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

Novo Nordisk stock toppled Monday after its weight-loss pill failed to significantly slow the progression of Alzheimer's ...

A Korean research team has identified the most effective OLED color capable of enhancing cognitive function in Alzheimer's ...

Findings from a prospective phase 2 clinical trial show that isatuximab (Sarclisa), an anti-CD38 monoclonal antibody, is an effective and well-tolerated treatment for patients with relapsed and/or ...

Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or ...

Controversial anti-amyloid therapies costing up to $32,000 annually offer modest hope for Alzheimer's patients while carrying ...

In the early 1980s, men and women in the prime of their lives began arriving at Walter Reed Medical Center, wrecked by a ...

Kavita Nair, PhD, FAAN, shares how new therapies and ongoing clinical trials are reshaping the future of neurological care and offering new hope to patients.

Current antibody-based treatments for Alzheimer’s disease remain costly and carry significant side effects, highlighting the ...

A new study shows that oral arginine, a naturally occurring amino acid, can significantly suppress amyloid-β aggregation in Alzheimer’s disease models.

Researchers discovered that the common amino acid arginine can block harmful Aβ aggregation and reduce its toxic effects in ...

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...